目的 探討六神丸口服治療肝經(jīng)郁熱型帶狀皰疹的臨床效果。方法 選取江西省皮膚病專科醫(yī)院2022年10月—2024年10月門診肝經(jīng)郁熱型帶狀皰疹患者100例，采用隨機(jī)數(shù)字表法分組，治療組和對(duì)照組每組各50例，對(duì)照組口服阿昔洛韋片及外用阿昔洛韋乳膏，治療組在對(duì)照組基礎(chǔ)上口服六神丸。比較兩組臨床療效、中醫(yī)證候積分、皮損評(píng)分、視覺(jué)模擬評(píng)分（visual analogue scale，VAS）、帶狀皰疹簡(jiǎn)明疼痛評(píng)估量表（zoster brief pain inventory，ZBPI）評(píng)分、匹茲堡睡眠量表（Pittsburgh sleep quality index，PSQI）評(píng)分、炎性因子、T淋巴細(xì)胞亞群、不良反應(yīng)發(fā)生率、帶狀皰疹后神經(jīng)痛（postherpetic neuralgia，PHN）發(fā)生率。結(jié)果 治療后，治療組總有效率（96.00%）和顯效率（78.00%）明顯優(yōu)于對(duì)照組（分別為84.00%和52.00%）（P＜0.05）。治療后，兩組中醫(yī)證候積分、皮損評(píng)分、VAS、ZBPI評(píng)分、PSQI評(píng)分均較治療前降低，且治療組顯著低于對(duì)照組（P＜0.01）。治療后，兩組的炎性因子［白細(xì)胞介素-1β（interleukin-1β，IL-1β）、IL-6、腫瘤壞死因子-α（tumor necrosis factor-α，TNF-α）］均較治療前降低，且治療組顯著低于對(duì)照組（P＜0.05）。治療后，兩組的T細(xì)胞CD4⁺、CD4⁺/CD8⁺較治療前升高，且治療組顯著高于對(duì)照組（P＜0.05），兩組CD8⁺均較治療前降低，且治療組顯著低于對(duì)照組（P＜0.05）。治療后，皮疹愈合后1個(gè)月及3個(gè)月，治療組的PHN發(fā)生率均明顯低于對(duì)照組（P＜0.05）；兩組均未發(fā)生不良反應(yīng)。結(jié)論 六神丸能快速消除帶狀皰疹皮損、強(qiáng)效止痛、改善睡眠、降低炎性因子水平、調(diào)節(jié)免疫，降低PHN發(fā)病率，顯著提高療效。

Objective To investigate the clinical efficacy of Liushen Pills in the treatment of herpes zoster with liver channel stagnation-heat type. Methods A total of 100 outpatients with herpes zoster of liver channel stagnation-heat type were selected from Jiangxi Provincial Dermatology Hospital from October 2022 to October 2024. They were randomly divided into two groups using a random number table: the treatment group and the control group, each with 50 patients. The control group was treated with oral acyclovir tablets, along with topical acyclovir cream. The treatment group received Liushen Pills orally in addition to the control group’s treatment. The clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, skin lesion scores, visual analog scale (VAS), zoster brief pain inventory (ZBPI), pittsburgh sleep quality index (PSQI), inflammatory factors, T lymphocyte subsets, incidence of adverse reactions, and incidence of postherpetic neuralgia (PHN) were compared between the two groups. Results After treatment, the total effective rate (96.00%) and the markedly effective rate (78.00%) in the treatment group were significantly better than those in the control group (84.00% and 52.00%, respectively) (P < 0.05). After treatment, the TCM syndrome scores, skin lesion scores, VAS, ZBPI, and PSQI scores in both groups decreased compared to before treatment, and the treatment group was significantly lower than the control group (P < 0.01). The levels of inflammatory factors [interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α)] in both groups decreased after treatment, and the treatment group was significantly lower than the control group (P < 0.05). The levels of CD4⁺ T cells and CD4⁺/CD8⁺ ratio increased in both groups after treatment, and the treatment group was significantly higher than the control group (P < 0.05). The CD8+ T cell levels decreased in both groups after treatment, and the treatment group was significantly lower than the control group (P < 0.05). One month and three months after the skin lesions healed, the incidence of PHN in the treatment group was significantly lower than that in the control group (P < 0.05). No adverse reactions occurred in either group. Conclusion Liushen Pills can rapidly eliminate herpes zoster skin lesions, provide strong pain relief, improve sleep, reduce inflammatory factor levels, regulate immunity, and lower the incidence of PHN, and significantly improve treatment efficacy.

R285.64

全國(guó)中醫(yī)藥工作示范單位（國(guó)中醫(yī)藥辦醫(yī)政發(fā)[2017]10號(hào)，洪衛(wèi)中醫(yī)字[2017]12號(hào)）；江西省中醫(yī)臨床重點(diǎn)?？?中西醫(yī)結(jié)合皮膚科（贛衛(wèi)中醫(yī)字2018 20號(hào)，贛中醫(yī)藥字[2016]1號(hào)文）；江西省中西醫(yī)臨床協(xié)作試點(diǎn)建設(shè)單位（贛中醫(yī)藥綜合字[2021]9號(hào)）